The Non-Melanoma Skin Cancer Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Non-melanoma skin cancers develop in the outermost layer of skin, known as epidermis. It is caused by increased exposure of genetic mutations, UV rays and ozone layer depletion. Non-melanoma skin cancer is mainly classified into two types. They are basal cell carcinoma and squamous cell carcinoma. Basal cell carcinoma is one of the most common types of skin cancers. It accounts about 70% of all skin cancers. Basal cell carcinoma starts underneath of the epidermis. Basal cell carcinoma usually appears as a red or pink lump. It usually develops on ears, face and neck. Squamous cell carcinoma accounts 20% of skin cancer. It starts on the upper side of epidermis. Squamous cell carcinoma appears as a red lump which develops into tumors. This type of cancer usually appears on that parts of the body which are directly exposed to the sun. It includes hands, face, ears, lips and legs.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3648
The global non-melanoma skin cancer market is categorized based on various types and by various treatment methods. Type segment comprises basal cell carcinoma and squamous cell carcinoma. Treatment segment is further sub-segmented into non-invasive treatments and chemotherapy treatment. Non-invasive treatments include laser therapy, radiotherapy, photodynamic therapy (PDT) cryotherapy and others. The chemotherapy sub-segment includes various treatment drugs for basal cell carcinoma and squamous cell carcinoma.
In terms of geographic, North America dominates the global non-melanoma skin cancer market. The U.S. represents the largest market for non-melanoma skin cancer followed by Canada in North America. In Europe, France, Germany, Italy, Spain and the U.K. holds major share of non-melanoma skin cancers market. However, Asia is expected to show high growth rates in the next five years in global non-melanoma skin cancer market. This is due to many companies constructing their manufacturing and research facilities in the region. In addition, rising awareness about skin cancer has also fueled the growth of non-melanoma skin cancer market in the region. Japan, China and India are expected to be the fastest growing non-melanoma skin cancer markets in Asia.
In recent time, increasing prevalence of skin cancer is key driver of global non-melanoma skin cancer market. In addition, extensive R&D pipelines and increasing usage of combination therapies have also fueled the growth of global non-melanoma skin cancer market.
However, stringent regulatory hurdles obstruct the growth of global non-melanoma skin cancer market. In addition, high risk of side-effect and complications associated with radiation therapy also impedes the growth of global non-melanoma skin cancer market. Some of the common side-effect of radiation therapy includes itchy or red skin and rashes. Advancement in biomedical science develops opportunity for the global non-melanoma skin cancer market. Rapid product launches and increasing mergers and acquisitions between manufacturing companies are some of the major trends of global non-melanoma skin cancer market.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/3648
Some of the major companies operating in the global non-melanoma skin cancer market are F. Hoffmann-la Roche Ltd., Valeant Pharmaceuticals Inc., Novartis International AG, Elekta AB, Varian Medical Systems Inc., Meda AB, iCAD Inc., Merck & Co. Inc., Eli Lilly and Co., Bristol Myers Squibb Co., Boehringer Ingelheim GmbH and Aqua Pharmaceuticals LLC.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353